A series of news updates on Edwards Lifesciences Corporation (EW) are taking the spotlight. Shares of EW have seen various movements, with multiple asset management firms, including Assenagon Asset Management and NewEdge Advisors LLC, divesting some of their holdings. Conversely, organizations like Capital Asset Advisory Services and Acadian Asset Management were reported to have acquired considerable amounts of EW's shares. The company also received a consensus rating of Moderate Buy from brokerages. Moreover, EW generated buzz with updates on its Earnings Reports, showcasing strong sales growth and raising expectations. The FTC, however, seeks to block Edwards Lifesciences' acquisition of JenaValve. Despite this, the company accelerated its share repurchase program worth $500 Million. Finally, EW has announced a product recall, causing a temporary dip in stock prices, but quickly bounced back following positive Q2 results and raised guidance. The firm is also making strides in the field of TAVR therapy, gaining FDA approval for a groundbreaking treatment for asymptomatic patients.
Edwards Lifesciences Corp EW News Analytics from Mon, 02 Dec 2024 08:00:00 GMT to Sat, 20 Sep 2025 12:53:55 GMT - Rating 4 - Innovation 5 - Information 7 - Rumor -3
